Chemosensitizing with liposomes containing oligonucleotides

Details Chemosensitizing with liposomes containing oligonucleotides Chemosensitizing with liposomes containing oligonucleotides

2007-08-28

2007-08-28

Zara, Jane (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C435S458000, C514S001000, C536S023100, C536S024500

Reexamination Certificate

active

10075994

ABSTRACT:
The invention relates to the use of oligonucleotide containing cationic liposomal formulations to enhance the efficacy of chemotherapy and/or radiotherapy, particularly as a means to sensitize cancerous tumor tissues to the efficiencies of chemotherapy. This is particularly advantageous in the context of treating raf expressing tumors such as breast, lung, pancreatic and prostate tumors.

REFERENCES:
patent: 5003097 (1991-03-01), Beaucage et al.
patent: 5026558 (1991-06-01), Hwang et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5283185 (1994-02-01), Epand et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5563255 (1996-10-01), Monia et al.
patent: 5641662 (1997-06-01), Debs et al.
patent: 5656612 (1997-08-01), Monia
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5696277 (1997-12-01), Hostetler et al.
patent: 5744362 (1998-04-01), Monia et al.
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5919619 (1999-07-01), Tullis
patent: 5919773 (1999-07-01), Monia et al.
patent: 5952229 (1999-09-01), Monia et al.
patent: 5981731 (1999-11-01), Monia
patent: 6027892 (2000-02-01), Chang et al.
patent: 6090626 (2000-07-01), Monia et al.
patent: 6096720 (2000-08-01), Love et al.
patent: 6114517 (2000-09-01), Monia et al.
patent: 6120798 (2000-09-01), Allen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6248351 (2001-06-01), Xing et al.
patent: 6333314 (2001-12-01), Kasid et al.
patent: 6358932 (2002-03-01), Monia
patent: 6391636 (2002-05-01), Monia
patent: 6410518 (2002-06-01), Monia
patent: 6461637 (2002-10-01), Rahman
patent: 6559129 (2003-05-01), Kasid et al.
patent: 2003/0215489 (2003-11-01), Kasid et al.
patent: 2003/0215492 (2003-11-01), Ahmad et al.
patent: 2003/0219476 (2003-11-01), Ahmad et al.
patent: 2003/0225023 (2003-12-01), Kasid et al.
patent: 2003/0228317 (2003-12-01), Gokhale et al.
patent: 2003/0229040 (2003-12-01), Kasid et al.
patent: 2004/0005603 (2004-01-01), Kasid et al.
patent: 2004/0082771 (2004-04-01), Kasid et al.
patent: 2004/0106571 (2004-06-01), Kasid et al.
patent: 2004/0115714 (2004-06-01), Kasid et al.
patent: 2004/0248218 (2004-12-01), Kasid et al.
patent: 2005/0002918 (2005-01-01), Strauss et al.
patent: 2005/0019387 (2005-01-01), Rahman et al.
patent: 2005/0148528 (2005-07-01), Gately
patent: 2005/0153297 (2005-07-01), Ahmad et al.
patent: 2005/0181037 (2005-08-01), Ahmad et al.
patent: 2005/0202074 (2005-09-01), Rahman
patent: 2005/0238706 (2005-10-01), Ahmad et al.
patent: 2005/0249795 (2005-11-01), Zhang et al.
patent: WO93/04170 (1993-03-01), None
patent: WO93/06248 (1993-04-01), None
patent: WO93/24640 (1993-12-01), None
patent: WO94/15645 (1994-07-01), None
patent: WO94/23755 (1994-10-01), None
patent: WO95/11670 (1995-05-01), None
patent: WO95/30330 (1995-11-01), None
patent: WO95/32987 (1995-12-01), None
patent: WO96/40062 (1996-12-01), None
patent: WO97/04787 (1997-02-01), None
patent: WO97/07784 (1997-03-01), None
patent: WO98/18489 (1998-05-01), None
patent: WO99/02167 (1999-01-01), None
patent: WO 01/70220 (2001-09-01), None
patent: WO 02/32400 (2002-04-01), None
patent: WO 02/058622 (2002-08-01), None
patent: WO 02/059337 (2002-08-01), None
Peracchi, A. Rev. Med. Viro. vol. 14, pp. 47-64 (2004).
Pihl-Carey, K. BioWorld Today. vol. 10, pp. 1-2 (1999).
Crooke, S. Antisense Res. and Application, pp. 1-50, (ed. by S. Crooke) Springer-Verlag (1999).
Branch, A. Trends in Biochem. Sci. vol 23, pp. 45-50 (1998).
Palu, G. et al. J. Biotech vol. 68, pp. 1-13 (1999).
Chirila, T. et al. Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al. Molecular Med. Today vol. 6, pp. 72-81 (2000).
Tamm,I. et al. The Lancet, vol. 358, pp. 489-497 (2001).
Bonner et al.,Nucl. Acid. Res., 14(2), 1009-15 (1988).
Carroll et al.,J. Biol. Chem., 266(23), 14964-69 (1991).
Kasid et al.,Science, 243, 1354-56 (1989).
Kizaka-Kondoh et al.,Mol. Cell. Biol., 12(11), 5078-86 (1992).
Kolch et al.,Nature, 349(6308), 426-28 (1991).
Monia et al.,Nature Med., 2(6), 668-75 (1996).
Patel et al.,Mol. Carcinogen, 8(1), 7-12 (1993).
Reidel et al.,Eur. J. Immunol., 23, 3146-50 (1993).
Törnkvist et al.,J. Biol. Chem., 269, 13919-921 (1994).
Gokhale et al., “Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer,”Gene Therapy, 4, 1289-1299 (1997).
Gokhale et al., “AntisenserafOligodeoxyribonucleotide is a Radiosensitizerin Vivo,” Antisense&Nucleic Acid Drug Development, 9 191-201 (1999).
James, “Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes,”Antiviral Chem.&Chemoth., 2, 191-214 (1991).
Kasid et al., “Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma,”Science, 243, 1354-1356 (1989).
Lappalainen et al., “Comparison of Cell Proliferation and Toxicity Assays Using Two Cationic Liposomes,”Pharmaceutical Research, 11(8), 1127-1131 (1994).
Litizinger et al., “Fate of cationic liposomes and their complex with oligonucleotide in vivo,”Biochimica et Biophisica Acta, 1281, 139-149 (1996).
Maher et al., “Specific Hybridization Arrest of Dihydrofolate Reductase mRNA in Vitro Using Anti-sense RNA or Anti-sense Oligonucleotides,”Archives of Biochemistry and Biophysics, 253, 214-220 (1987).
Milner et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays,”Nature Biotechnology, 15, 537-541 (1997).
Patel et al., “Nucleotide Sequence Analysis of c-raf-1 cDNA and Promoter From a Radiation-Resistant Human Squamous Carcinoma Cell Line: Deletion Within Exon 17,”Molecular Carcinogenesis, 8, 7-12 (1993).
Schofield et al., “Non-viral approaches to gene therepy,”Brit. Med. Bull., 51, 56-71 (1995).
Seung et al., “Genetic Radiotherapy Overcomes Tumor Resistance to Cytotoxic Agent,”Cancer Research, 55, 5561-5565 (1995).
Soldaatenkov et al., “Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation,”Cancer J. Sci. Am., 3, 13-20 (1997).
Verma et al., “Gene therapy—promises, problems and prospects,”Nature, 389, 239-242 (1997).
Branch, “A Good Antisense Molecule is Hard to Find,”TIBS, 23, 45-50 (1998).
Crooke, “Antisense Research and Application,”Springer-Verlag, 1, 1-50 (1998).
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,”Science, 270, 404-410 (1995).
Friedmann, “Overcoming the Obstacles to Gene Therapy,”Science America, Jun., 96-101 (1997).
Gokhale et al., “Enhanced inhibition of Raf-1 Kinase by liposomal antisense raf oligodeoxyribonucleotide in human squamous carcinoma cells,”American Asso. Cancer Research, 37, Poster Section 6 #2807 (1996).
U.S. Appl. No. 11/010,158, filed Dec. 10, 2004, Kasid et al.
Bennet et al.,Molecular Pharmacology, 41(6), 1023-1033 (1992).
Bonner et al.,Nucleic Acid Research, 14(2), 1009-1015 (1986).
Felgner,Human Gene Therapy, 7, 1791-1793 (1996).
Gokhale, “Antisense 97: Targeting the Molecular Basis of Disease”, Cambridge Symposium Meeting, May 1997.
Kasid et al., “Stress response signal transduction: emerging concepts and biological significance”,Apoptosis Genes, Kluwer Academic Pub. 85-118 (1998).
Litzinger,J. Liposome Research, 7(1), 51-61 (1997).
Thiery et al.,Biochemical Biophysical Research Communications, 190(3), 952-960 (1993).
Troppmair et al.,Curr. Top. Microbiol. Immunol., 182, 453-60 (1992).
Wang et al.,Cell, 87, 629-638 (1996).
Weissinger et al.,Molecular Cell Biology, 17(6), 3229-3241 (1997).
Zelphati et al.,J. Liposome Research, 7(1), 31-49 (1997).
Zhan et al.,Onco

Affiliated with

Also associated with

Rating

Chemosensitizing with liposomes containing oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemosensitizing with liposomes containing oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemosensitizing with liposomes containing oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3852850